25 Years of Proton Pump Inhibitors: A Comprehensive Review

키워드

참고문헌 (102)

1. Farley A, "Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease:a double-blind, randomized clinical trial: Raberprazole Study Group", Am J Gastroenterol, 95, pp.1894~1899 (2000)
2. Huang JQ, "pH, healing rate and symptom relief in acidrelated diseases", Yale J Biol Med, 69, pp.159~174 (1996)
3. "Proton pump inhibitors: U.S. Food and Drug Administration-approved indications and dosages for use in adults" (2014)[URL]
4. Chiba N, "Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:a meta-analysis", Gastroenterology, 112, pp.1798~1810 (1997)
5. Lassen AT, "Acid-related disorders and use of antisecretory medication", Dan Med Bull, 54, pp.18~30 (2007)
6. Shi S, "Proton pump inhibitors: an update of their clinical use and pharmacokinetics", Eur J Clin Pharmacol, 64, pp.935~951 (2008)
7. Klotz U, "Pharmacokinetic considerations in the eradication of Helicobacter pylori", Clin Pharmacokinet, 38, pp.243~270 (2000)
8. Esplugues JV, "Safety of proton pump inhibitors", Med Clin (Barc), 127, pp.790~795 (2006)
9. Maffei M, "Side effects of proton pump inhibitors (PPIs)", Rev Med Suisse, 3, pp.1934~1936 (2007)
10. Sachs G, "Review article: the clinical pharmacology of proton pump inhibitors", Aliment Pharmacol Ther, 23(Suppl 2), pp.2~8 (2006)
11. Morelli G, "An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers", Aliment Pharmacol Ther, 33, pp.845~854 (2011)
12. Vakily M, "Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials", Curr Med Res Opin, 25, pp.627~638 (2009)
13. Williams MP, "Review article: the pharmacology of rabeprazole", Aliment Pharmacol Ther, 13(Suppl 3), pp.3~10 (1999)
14. Furuta T, "Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer", Ann Intern Med, 129, pp.1027~1030 (1998)
15. Hagymási K, "Update on the pharmacogenomics of proton pump inhibitors", Pharmacogenomics, 12, pp.873~888 (2011)
16. Wolfe MM, "Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome", Gastroenterology, 18, pp.S9~S31 (2000)
17. Howden CW, "Optimizing the pharmacology of acid control in acid-related disorders", Am J Gastroenterol, 92(4 Suppl), pp.17S~19S (1997)
18. Wilder-Smith CH, "Tolerance to oral H2-receptor antagonists", Dig Dis Sci, 35, pp.976~983 (1990)
19. Prichard PJ, "The effectiveness of ranitidine in reducing gastric acidsecretion decreases with continued therapy", Br J Clin Pharmacol, 22, pp.663~668 (1986)
20. Hunt RH, "Optimizing acid suppression for treatment of acid-related diseases", Dig Dis Sci, 40(2Suppl), pp.24S~49S (1995)
21. Eriksson S, "Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a metaanalysis", Eur J Gastroenterol Hepatol, 7, pp.467~475 (1995)
22. Morgan DG, "Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis", Gastroenterology, 104, pp.A150~ (1993)
23. Poynard T, "Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer", Eur J Gastroenterol Hepatol, 7, pp.661~665 (1995)
24. Prakash A, "Rabeprazole", Drugs, 55, pp.261~267 (1998)
25. Fitton A, "Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders", Drugs, 51, pp.460~482 (1996)
26. Lauritsen K, "Omeprazole 20 mgthree days a week and 10 mg daily in prevention of duodenal ulcer relapse: double-blind comparative trial", Gastroenterology, 100, pp.663~669 (1991)
27. Lanza F, "Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebocontrolled study. The Lansoprazole Study Group", Dig Dis Sci, 42, pp.2529~2536 (1997)
28. Dammann HG, "Efficacy of continuous therapy for peptic ulcer in controlled clinical trials", Aliment Pharmacol Ther, 7(Suppl 2), pp.17~25 (1993)
29. Katschinski B, "Prognostic factors in upper gastrointestinal bleeding", Dig Dis Sci, 39, pp.706~712 (1994)
30. Laine L, "Management of patients with ulcer bleeding", Am J Gastroenterol, 107, pp.345~360 (2012)
31. Barkun AN, "International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding", Ann Intern Med, 152, pp.101~113 (2010)
32. Barkun A, "Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding", Ann Intern Med, 139, pp.843~857 (2003)
33. Sreedharan A, "Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding", Cochrane Database Syst Rev, (7), pp.CD005415~ (2010)
34. Laine L, "Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials", Clin Gastroenterol Hepatol, 7, pp.33~47 (2009)
35. Laine L, "Bleeding peptic ulcer", N Engl J Med, 331, pp.717~727 (1994)
36. Marshall BJ, "Helicobacter pylori", Am J Gastroenterol, 89(8Suppl), pp.S116~S128 (1994)
37. Shimada T, "Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users", Nihon Rinsho, 65, pp.1824~1829 (2007)
38. Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus report, 2012, pp.61, 646~664
39. Yuan Y, "Optimum duration of regimens for Helicobacter pylori eradication", Cochrane Database Syst Rev, (12), pp.CD008337~ (2013)
40. Welage LS, "Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases", J Am Pharm Assoc (Wash), 40, pp.52~62 (2000)
41. Lundell L, "Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial", Aliment Pharmacol Ther, 23, pp.639~647 (2006)
42. Moayyedi P, "Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression", Helicobacter, 5, pp.206~214 (2000)
43. Kuipers EJ, "Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication", N Engl J Med, 334, pp.1018~1022 (1996)
44. Hagiwara T, "Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori", Gut, 60, pp.624~630 (2011)
45. Fox JG, "Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil", Gut, 60, pp.567~568 (2011)
46. Gabriel SE, "Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis", Ann Intern Med, 115, pp.787~796 (1991)
47. Wallace JL, "Nonsteroidal anti-inflammatory drugs and gastroenteropathy:the second hundred years", Gastroenterology, 112, pp.1000~1016 (1997)
48. Bhatt DL, "ACCF", ACG, J Am Coll Cardiol, pp.2008, 52[DOI]
49. Lanza FL, "Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications", Am J Gastroenterol, 104, pp.728~738 (2009)
50. Taha AS, "Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs", N Engl J Med, 334, pp.1435~1439 (1996)
51. Taha AS, "Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, doubleblind, placebo-controlled trial", Lancet, 374, pp.119~125 (2009)
52. Koch M, "Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury:a meta-analysis of randomized controlled clinical trials", Arch Intern Med, 156, pp.2321~2332 (1996)
53. Tuskey A, "The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage", Arthritis Res Ther, 15(Suppl 3), pp.S6~ (2013)
54. Tamura A, "OITA-GF Study Investigators. Prevalence and independent factors for gastroduodenal ulcers", erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study, 2011, pp.104, 133~139
55. Scheiman JM, "Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors", Am J Gastroenterol, 101, pp.701~710 (2006)
56. Jensen RT, "Zollinger-Ellison syndrome: advances intreatment of gastric hypersecretion and the gastrinoma", JAMA, 271, pp.1429~1435 (1994)
57. Maton PN, "Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome:a prospective study", Gastroenterology, 97, pp.827~836 (1989)
58. Hirschowitz BI, "Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study", Clin Gastroenterol Hepatol, 3, pp.39~48 (2005)
59. Metz DC, "Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high", Gastroenterology, 103, pp.1498~1508 (1992)
60. El-Serag HB, "Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review", Gut, 63, pp.871~880 (2014)
61. Dent J, "Epidemiology of gastro-oesophageal reflux disease: a systematic review", Gut, 54, pp.710~717 (2005)
62. 이시형, "Endoscopic Experience Improves Interobserver Agreement in the Grading of Esophagitis by Los Angeles Classification: Conventional Endoscopy and Optimal Band Image System", Gut and Liver, 8(2), pp.154~159 (2014), 거트앤리버 발행위원회
63. Fass R, "Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release", Clin Gastroenterol Hepatol, 10, pp.247~253 (2012)
64. Khan M, "Medical treatments in the short term management of reflux oesophagitis", Cochrane Database Syst Rev, (2), pp.CD003244~ (2007)
65. Vigneri S, "A comparison of five maintenance therapies for reflux esophagitis", N Engl J Med, 333, pp.1106~1110 (1995)
66. Kushner PR, "Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect", Adv Ther, 28, pp.367~388 (2011)
67. Kahrilas PJ, "American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease", Gastroenterology, 135, pp.1392~1413.e5 (2008)
68. Sigterman KE, "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease", Cochrane Database Syst Rev, (5), pp.CD002095~ (2013)
69. Shaheen NJ, "Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians", Ann Intern Med, 157, pp.808~816 (2012)
70. Katz PO, "Guidelines for the diagnosis and management of gastroesophageal reflux disease", Am J Gastroenterol, 108, pp.308~328 (2013)
71. Standards of Practice Committee, "Role of endoscopy in the management of GERD", Gastrointest Endosc, 66, pp.219~224 (2007)
72. Metz DC, "On-demand therapy for gastroesophageal reflux disease", Am J Gastroenterol, 102, pp.642~653 (2007)
73. Pace F, "Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’", Aliment Pharmacol Ther, 26, pp.195~204 (2007)
74. Nyrén O, "Economic costs of functional dyspepsia", Pharmacoeconomics, 1, pp.312~324 (1992)
75. Talley NJ, "Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebocontrolled trials (the Bond and Opera studies)", Aliment Pharmacol Ther, 12, pp.1055~1065 (1998)
76. Peura DA, "Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials", Am J Med, 116, pp.740~748 (2004)
77. Stanghellini V, "Editorial: reflux, dyspepsia, and Rome III (or Rome IV?)", Am J Gastroenterol, 105, pp.2632~2634 (2010)
78. Fass R, "Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease--where next", Aliment Pharmacol Ther, 22, pp.79~94 (2005)
79. Chey WD, "Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?", Dig Dis Sci, 55, pp.3415~3422 (2010)
80. Tutuian R, "Nocturnal acid breakthrough: approach to management", MedGenMed, 6, pp.11~ (2004)
81. DeVault KR, "American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease", Am J Gastroenterol, 100, pp.190~200 (2005)
82. Chey WD, "Treatment patterns and symptom control in patients with GERD: US community-based survey", Curr Med Res Opin, 25, pp.1869~1878 (2009)
83. Yuan Y, "Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers:evidence of an unmet need", Am J Gastroenterol, 103(Suppl 1), pp.S50~ (2008)
84. Chey WD, "Howden CW. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey", Am J Gastroenterol, 100, pp.1237~1242 (2005)
85. Ito T, "Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium", Curr Gastroenterol Rep, 12, pp.448~457 (2010)
86. Yang YX, "Long-term proton pump inhibitor therapy and risk of hip fracture", JAMA, 296, pp.2947~2953 (2006)
87. Kaye JA, "Proton pump inhibitor use and risk of hip fractures in patients without major risk factors", Pharmacotherapy, 28, pp.951~959 (2008)
88. Ngamruengphong S, "Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies", Am J Gastroenterol, 106, pp.1209~1218 (2011)
89. Eom CS, "Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis", CMAJ, 183, pp.310~319 (2011)
90. Filion KB, "Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis", Gut, 63, pp.552~558 (2014)
91. Sarkar M, "Proton-pump inhibitor use and the risk for community-acquired pneumonia", Ann Intern Med, 149, pp.391~398 (2008)
92. Lo WK, "Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis", Clin Gastroenterol Hepatol, 11, pp.483~490 (2013)
93. Bavishi C, "Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection", Aliment Pharmacol Ther, 34, pp.1269~1281 (2011)
94. Kwok CS, "Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis", Am J Gastroenterol, 107, pp.1011~1019 (2012)
95. Abraham NS, "ACCF", ACG, ACG, pp.AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use, Am J Gastroenterol[DOI]
96. "FDA drug safety communication:low magnesium levels can be associated with longterm use of proton pump inhibitor drugs (PPIs)" (2011)[URL]
97. Galmiche JP, "A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers", Aliment Pharmacol Ther, 21, pp.575~582 (2005)
98. Hunt RH, "Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers", Am J Gastroenterol, 100, pp.1949~1956 (2005)
99. Thomson AB, "Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study", Aliment Pharmacol Ther, 23, pp.1179~1187 (2006)
100. Laine L, "Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis. The results of two double-blind studies", Aliment Pharmacol Ther, 33, pp.203~212 (2011)
101. Fass R, "The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD", Am J Gastroenterol, 106, pp.421~431 (2011)
102. Chowers Y, "The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH", Neurogastroenterol Motil, 24, pp.426~431.e209 (2012)

관련 논문AI추천